News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Active Biotech AB Interim Report January-June 2007
August 9, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN--(MARKET WIRE)--Aug 9, 2007 -- * Laquinimod: Phase III trials initiated * ANYARA: orphan drug status granted by EMEA * TASQ: Phase I study concluded
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
October 2, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together
October 2, 2025
·
2 min read
·
Tristan Manalac
Cell therapy
Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality
October 2, 2025
·
2 min read
·
Tristan Manalac
Cancer
AnaptysBio Plans Business Split To Sharpen Focus on Asset Value
October 1, 2025
·
2 min read
·
Tristan Manalac
